Immunotherapy and multiple sclerosis: new insights and new challenges in 2016 Review article
Article Sidebar
Published:
Sep 30, 2016
Keywords:
multiple sclerosis, MS, immunotherapy
Main Article Content
Abstract
Multiple sclerosis is an autoimmune, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus mainly on preventing new exacerbations and avoiding the progression and the disability causing by the MS. This has led to the development and investigation of new drugs. Recent clinical trials and meta-analyses suggest that new monoclonal antibodies: alemtuzumab and ocrelizumab as well as teriflunomide could be a promising option in MS immunotherapy.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Linker R.A., Haghikia A.: Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther. Adv. Chronic Dis. 2016; 7(4): 198-207.
2. Cocco E., Marrosu M.G.: Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther. Clin. Risk Manag. 2015; 11: 759-766.
3. Ghezzi A., Moiola L., Pozzilli C. et al.: Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15: 174.
4. O’Connor P.W., Kremenchutzky M.: Use of natalizumab in patients with multiple sclerosis: 2015 Update. Can. J. Neurol. Sci. 2015; 42(6): 372-380.
5. Riera R., Porfírio G.J., Torloni M.R.: Alemtuzumab for multiple sclerosis. Cochrane Database Syst. Rev. 2016; 4: CD011203.
6. Ruck T., Afzali A.M., Lukat K.F. et al.: ALAIN01 – Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurol. 2016; 16: 34.
7. Xu M., Lu X., Fang J. et al.: The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials. J. Clin. Neurosci. 2016; [pii: S0967-5868(16)30358-7], [doi: 10.1016/j.jocn.2016.02.041].
8. Sorensen P.S., Blinkenberg M.: The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther. Adv. Neurol. Disord. 2016; 9(1): 44-52.
2. Cocco E., Marrosu M.G.: Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther. Clin. Risk Manag. 2015; 11: 759-766.
3. Ghezzi A., Moiola L., Pozzilli C. et al.: Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15: 174.
4. O’Connor P.W., Kremenchutzky M.: Use of natalizumab in patients with multiple sclerosis: 2015 Update. Can. J. Neurol. Sci. 2015; 42(6): 372-380.
5. Riera R., Porfírio G.J., Torloni M.R.: Alemtuzumab for multiple sclerosis. Cochrane Database Syst. Rev. 2016; 4: CD011203.
6. Ruck T., Afzali A.M., Lukat K.F. et al.: ALAIN01 – Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurol. 2016; 16: 34.
7. Xu M., Lu X., Fang J. et al.: The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials. J. Clin. Neurosci. 2016; [pii: S0967-5868(16)30358-7], [doi: 10.1016/j.jocn.2016.02.041].
8. Sorensen P.S., Blinkenberg M.: The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther. Adv. Neurol. Disord. 2016; 9(1): 44-52.